Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
2020
Biannual infusions with rituximab for 18 months have become the standard of care for maintaining remission in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV). This ran...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
35
Citations
NaN
KQI